DataMEDS AI, Inc. (MEDS) stock forecast & analysis
3.76
NasdaqCM · USD
Down: -0.88, -19.0%
4.05Up: +0.29, +7.7%
1 analysis
- Open
- 5.96
- Previous close
- 4.64
- Day range
- 3.45 – 6.29
- 52-week range
- 0.8230 – 73.00
- Volume (shares)
- 15.67M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 3.20M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- Not available
- Market cap
- 12.02M
Market Scanner’s AI analysis of DataMEDS AI, Inc. (MEDS), updated September 2026: DataMEDS AI's acquisition of Helomics AI and expansion into cancer diagnostics contrasted with significant revenue decline and negative margins.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of DataMEDS AI, Inc. (MEDS) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
DataMEDS AI's acquisition of Helomics AI and expansion into cancer diagnostics contrasted with significant revenue decline and negative margins.
Recent analyses for MEDS covered a significant strategic acquisition of Helomics AI, expanding the company into cancer diagnostics and precision oncology. This move is juxtaposed with substantial financial headwinds, including a sharp year-over-year quarterly revenue decline and persistent negative operating margins. Market analysis noted a recent short-term price surge alongside a strong downtrend indicated by moving averages, with mixed signals from momentum indicators.
MEDS news & sentiment
News reports highlighted a major strategic acquisition and new marketing initiatives, signaling expansion. Social media discussions were not covered in the provided notes.
MEDS technical picture
The MEDS stock experienced a significant short-term surge, contrasting with a longer-term decline, as the price traded near the upper Bollinger Band. Moving averages indicated a strong downtrend, though recent momentum readings showed some upward movement from negative territory. Momentum indicators presented mixed signals, with RSI in neutral territory and MFI suggesting strong buying pressure.
Fundamentals
The company experienced a significant year-over-year quarterly revenue decline and faces substantial profitability challenges, with negative gross and operating margins. Net income has been consistently negative across all reported periods.
Factors discussed — upside
- Completion of acquisition of Helomics AI Cancer Diagnostics Lab and associated businesses.
- Launch of marketing campaigns with NFL Alumni Association and for Galectovid(TM).
- High Money Flow Index (MFI) suggesting strong buying pressure.
- Recent upward trend in MACD values.
Factors discussed — risks
- Significant year-over-year quarterly revenue decline of 77.2%.
- Negative Operating Margin TTM of 412.7%.
- Negative Gross Profit TTM.
- Stock price below 50-day and 200-day SMAs, indicating a strong downtrend.
- Consistently negative net income across reported periods.
- Strategic Acquisitions
- Financial Performance
- Market Momentum
- Healthcare Sector Expansion
Summary updated .
MEDS technical indicators
Common technical indicators for MEDS, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 2.18 | Price above |
| 10-day exponential moving average | 2.70 | Price above |
| Relative strength index (14-day) | 61.99 | Neutral |
| MACD line (12/26/9) | 0.4386 | Above its signal line |
| Bollinger bands (20-day, 2σ) | -1.16 – 4.45 | Price inside the bands |
Analyses
Recent MEDS.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for DataMEDS AI, Inc.?
- The bull case centers on DataMEDS AI's strategic expansion into cancer diagnostics and precision oncology through the acquisition of Helomics AI, complemented by marketing initiatives and strong buying pressure indicated by the Money Flow Index. Recent upward trends in MACD values also suggest potential positive momentum.
- What are the risks for DataMEDS AI, Inc.?
- The bear case highlights significant financial challenges, including a substantial year-over-year quarterly revenue decline, negative gross and operating margins, and consistently negative net income. Additionally, the stock price remains below key moving averages, indicating a strong downtrend.
- Is DataMEDS AI, Inc. bullish or bearish?
- Recent AI analyses of DataMEDS AI, Inc. examined factors on both sides. Discussed upside: The bull case centers on DataMEDS AI's strategic expansion into cancer diagnostics and precision oncology through the acquisition of Helomics AI, complemented by marketing initiatives and strong buying pressure indicated by the Money Flow Index. Recent upward trends in MACD values also suggest potential positive momentum. Discussed risks: The bear case highlights significant financial challenges, including a substantial year-over-year quarterly revenue decline, negative gross and operating margins, and consistently negative net income. Additionally, the stock price remains below key moving averages, indicating a strong downtrend. These are descriptive observations, not a recommendation.
- What is the latest sentiment on DataMEDS AI, Inc.?
- News reports highlighted a major strategic acquisition and new marketing initiatives, signaling expansion. Social media discussions were not covered in the provided notes.
- How does Market Scanner analyse DataMEDS AI, Inc.?
- Every analysis of DataMEDS AI, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
- Bundles used
- gemini-low-v2
Run a fresh MEDS.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.
Or sign in to read every MEDS.US report already in the library